Medpace (NASDAQ:MEDP – Get Free Report) issued an update on its FY24 earnings guidance on Monday morning. The company provided earnings per share guidance of $11.71-12.09 for the period, compared to the consensus earnings per share estimate of $11.59. The company issued revenue guidance of $2.09-2.13 billion, compared to the consensus revenue estimate of $2.13 billion. Medpace also updated its FY 2024 guidance to 11.710-12.090 EPS.
Medpace Stock Up 1.1 %
NASDAQ:MEDP opened at $330.07 on Thursday. Medpace has a 52 week low of $239.00 and a 52 week high of $459.77. The company has a fifty day simple moving average of $353.71 and a two-hundred day simple moving average of $382.20. The company has a market cap of $10.23 billion, a price-to-earnings ratio of 33.65, a price-to-earnings-growth ratio of 1.77 and a beta of 1.35.
Medpace (NASDAQ:MEDP – Get Free Report) last released its earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping the consensus estimate of $2.77 by $0.24. The firm had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. Medpace’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.22 EPS. On average, analysts expect that Medpace will post 11.64 EPS for the current year.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on Medpace
Medpace Company Profile
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Recommended Stories
- Five stocks we like better than Medpace
- Dividend Capture Strategy: What You Need to Know
- CrowdStrike Sees Unusual Call Option Surge: What’s Next?
- When to Sell a Stock for Profit or Loss
- GM Stock Is Crushing the Competition in 2024 – Is It Time to Buy?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- The Nuclear Shift: 3 Best Uranium ETFs to Invest in for 2024
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.